noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Healthcare

Pappas Capital LLC

07/25/2007 | Press release | Archived content

Athersys begins Phase I trial for ATHX-105 for treatment of obesity

News | 07. 25. 2007

Athersys

Athersys, Inc., a wholly owned subsidiary of BTHC VI (OTC Bulletin Board: BVIC), announced today that it has initiated a Phase I clinical trial in the United Kingdom for ATHX-105, the company's oral, selective 5HT2c receptor agonist for treating obesity.

Pappas Capital LLC published this content on July 25, 2007, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:12 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format